Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MEDI7352 for IV infusion
MEDI7352 for infusion · 1 trial · 1 indication
Adverse events, serious adverse events,
| Arm | Type | Description |
|---|---|---|
| MEDI7352 IV | EXPERIMENTAL | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| IV Placebo | PLACEBO_COMPARATOR | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| MEDI7352 Subcutaneous Injection | EXPERIMENTAL | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Name | Type | Description |
|---|---|---|
| MEDI7352 for IV infusion | BIOLOGICAL | MEDI7352 for IV infusion |
| Placebo for IV infusion | BIOLOGICAL | IV Placebo infusion |
| MEDI7352 for Subcutaneous Injection | BIOLOGICAL | MEDI7352 for subcutaneous injection |
| Placebo for Subcutaneous Injection | BIOLOGICAL | Subcutaneous Placebo Injection |
Inclusion Criteria: * Male and female subjects with painful osteoarthritis (OA) of the knee. Female subjects must be postmenopausal or surgically sterile. * Body weight between 50kg and 145kg * Willing and able to comply with the requirements of the protocol Exclusion Criteria: * Current treatmen...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
MEDI7352 for infusion is an investigational monoclonal antibody being studied for chronic pain, specifically painful osteoarthritis of the knee. It is administered intravenously. The Phase 1 trial enrolled adults with chronic pain related to knee osteoarthritis, and the program is being developed by AstraZeneca.
MEDI7352 for infusion is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 clinical trial evaluating the drug in patients with painful osteoarthritis of the knee.
MEDI7352 for infusion is in Phase 1 clinical development. The single completed trial, NCT02508155, was a Phase 1 study. There are currently no active trials listed for this asset, and it is not approved for any indication.
MEDI7352 for infusion has been evaluated in one completed Phase 1 trial, NCT02508155, titled A Study of MEDI7352 in Painful Osteoarthritis of the Knee. The trial enrolled 132 adults across Germany, Sweden, and the United Kingdom and was randomized, double-blind, and placebo-controlled.
Yes, MEDI7352 for infusion and MEDI7352 for IV infusion refer to the same investigational monoclonal antibody developed by AstraZeneca. The IV designation indicates intravenous administration, which is the route used in the Phase 1 trial for chronic pain in knee osteoarthritis.